GlassScriptPhysician profile
Muazer Ahmed
NPI 1891113577
$2,061.37
in general payments reported to CMS, 2019-2025
21 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $36.04 · 2021: $106 · 2022: $411 · 2023: $541 · 2024: $488 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508 · Education: $0.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.87 |
| Education | $0.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $280.16 | 2023-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $274.63 | 2022-2025 | Tarpeyo |
| Amgen INC. | $196.18 | 2022-2025 | Tavneos |
| Aurinia Pharma U.S., INC. | $188.22 | 2021-2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $128.39 | 2020-2024 | Velphoro |
| Ardelyx, INC. | $122.71 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $119.02 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $104.38 | 2022-2023 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.23 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $87.87 | 2022-2023 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $82.99 | 2021-2023 | Veltassa |
| Novartis Pharmaceuticals Corporation | $72.57 | 2024-2025 | |
| Travere Therapeutics, INC. | $65.47 | 2023-2025 | Filspari |
| Akebia Therapeutics INC | $59.39 | 2025 | Vafseo |
| Otsuka America Pharmaceutical, INC. | $39.56 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $38.04 | 2022 | |
| Novo Nordisk INC | $27.86 | 2021-2025 | Rybelsus, Ozempic |
| Kyowa Kirin, INC. | $24.97 | 2023 | Crysvita |
| Amag Pharmaceuticals, INC. | $16.99 | 2022 | |
| Coherus Oncology, INC. | $16.56 | 2020 | |
| Horizon Therapeutics Plc | $14.18 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muazer Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.